About this trial
Antiphospholipid syndrome is a thrombo-inflammatory autoimmune disorder with a complex antiphospholipid antibody-mediated pathogenesis, and high heterogeneity in clinical presentation and disease course. Clinical presentation in antiphospholipid syndrome includes venous and arterial thrombosis, pregnancy complications, and a broad range of microvascular and non-thrombotic manifestations
Eligibility criteria
Qualifiers
Adults (age ≥18 years)
Diagnosis of APS based on updated Sydney classification criteria confirmed by: Clinical history of thrombosis and/or pregnancy morbidity, Persistent presence (≥12 weeks) of antiphospholipid antibodies (aCL, anti-β2-glycoprotein I, and/or lupus anticoagulant)
Disqualifiers
Current infection or inflammatory condition unrelated to APS
Hematological malignancies or other blood disorders
Recent blood transfusion or platelet-altering medications other than APS treatments
Trial design
Treatments tested in this trial
- • Complete blood count , MPV
- Calculation of PLR: Platelet count / Lymphocyte count and Calculation of NLR:
- Antiphospholipid antibody profile